Lalchandani Usha R, Sahai Vaibhav, Hersberger Katherine, Francis Isaac R, Wasnik Ashish P
Tumor Response Assessment Core (TRAC), Rogel Cancer Center, University of Michigan Health System-Michigan Medicine, Ann Arbor, MI, 48109.
Tumor Response Assessment Core (TRAC), Rogel Cancer Center, University of Michigan Health System-Michigan Medicine, Ann Arbor, MI, 48109; Department of Internal Medicine, University of Michigan Health System-Michigan Medicine, Ann Arbor, MI, 48109.
Curr Probl Diagn Radiol. 2019 Nov-Dec;48(6):576-585. doi: 10.1067/j.cpradiol.2018.07.016. Epub 2018 Aug 2.
Response Evaluation Criteria in Solid Tumors (RECIST), including version 1.0 and 1.1, has been universally accepted as the standard response assessment criteria for conventional chemotherapies. Increasing use of immunotherapy led to the need and development of immune-related RECIST. Imaging plays a crucial role in response assessment for solid tumors in guiding patient management as well as in clinical trials. Familiarity to different response criteria will help radiologists to optimally identify, select, and measure tumor lesions per the criteria and assess response to therapy. This article provides a comprehensive review of published RECIST criteria.
实体瘤疗效评价标准（RECIST），包括1.0版和1.1版，已被普遍接受为传统化疗的标准疗效评估标准。免疫疗法的使用日益增加，导致了免疫相关RECIST的需求和发展。影像学在实体瘤疗效评估中起着关键作用，可指导患者管理以及临床试验。熟悉不同的疗效标准将有助于放射科医生根据标准最佳地识别、选择和测量肿瘤病变，并评估治疗反应。本文对已发表的RECIST标准进行了全面综述。
